P T T Kinnunen1,2, T J Murtola3,4, K Talala5, K Taari6, T L J Tammela3,4, A Auvinen7. 1. School of Medicine, University of Tampere, Tampere, Finland. Kinnunen.Pete.T@student.uta.fi. 2. Faculty of Medicine and Life Sciences, University of Tampere, Lääkärinkatu 1, 33520, Tampere, Finland. Kinnunen.Pete.T@student.uta.fi. 3. School of Medicine, University of Tampere, Tampere, Finland. 4. Department of Urology, Tampere University Hospital, Tampere, Finland. 5. Finnish Cancer Registry, Helsinki, Finland. 6. Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 7. Department of Epidemiology, University of Tampere, Tampere, Finland.
Abstract
PURPOSE: Anticoagulants may reduce mortality of cancer patients, though the evidence remains controversial. We studied the association between different anticoagulants and cancer death. METHODS: All anticoagulant use during 1995-2015 was analyzed among 75,336 men in the Finnish Randomized Study of Screening for Prostate Cancer. Men with prevalent cancer were excluded. Multivariable Cox regression was performed to compare risk of death from any cancer and disease-specific death from 9 specific cancer types between (1) anticoagulant users overall and (2) warfarin users compared to anticoagulant non-users and (3) warfarin or (4) low-molecular-weight heparins (LMWH) compared to users of other anticoagulants. Medication use was analyzed as time-dependent variable to minimize immortal time bias. 1-, 2- and 3-year lag-time analyses were performed. RESULTS: During a median follow-up of 17.2 years, a total of 27,233 men died of whom 8033 with cancer as the primary cause of death. In total, 32,628 men (43%) used anticoagulants. Any anticoagulant use was associated with an increased risk of cancer death (HR = 2.50, 95% CI 2.37-2.64) compared to non-users. Risk was similar independent of the amount, duration, or intensity of use. The risk increase was observed both among warfarin and LMWH users, although not as strong in warfarin users. Additionally, cancer-specific risks of death were similar to overall cancer mortality in all anticoagulant categories. CONCLUSION: Our study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.
RCT Entities:
PURPOSE: Anticoagulants may reduce mortality of cancerpatients, though the evidence remains controversial. We studied the association between different anticoagulants and cancer death. METHODS: All anticoagulant use during 1995-2015 was analyzed among 75,336 men in the Finnish Randomized Study of Screening for Prostate Cancer. Men with prevalent cancer were excluded. Multivariable Cox regression was performed to compare risk of death from any cancer and disease-specific death from 9 specific cancer types between (1) anticoagulant users overall and (2) warfarin users compared to anticoagulant non-users and (3) warfarin or (4) low-molecular-weight heparins (LMWH) compared to users of other anticoagulants. Medication use was analyzed as time-dependent variable to minimize immortal time bias. 1-, 2- and 3-year lag-time analyses were performed. RESULTS: During a median follow-up of 17.2 years, a total of 27,233 men died of whom 8033 with cancer as the primary cause of death. In total, 32,628 men (43%) used anticoagulants. Any anticoagulant use was associated with an increased risk of cancer death (HR = 2.50, 95% CI 2.37-2.64) compared to non-users. Risk was similar independent of the amount, duration, or intensity of use. The risk increase was observed both among warfarin and LMWH users, although not as strong in warfarin users. Additionally, cancer-specific risks of death were similar to overall cancer mortality in all anticoagulant categories. CONCLUSION: Our study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.
Entities:
Keywords:
Anticoagulant; Cancer mortality; Cohort; Low-molecular weight heparins; Warfarin
Authors: Jiro Ichikawa; Heather A Cole; Robert A Magnussen; Nicholas A Mignemi; Matthew Butler; Ginger E Holt; Lynda O'Rear; Masato Yuasa; Baldeep Pabla; Hirotaka Haro; Justin M M Cates; Heidi E Hamm; Herbert S Schwartz; Jonathan G Schoenecker Journal: Cancer Date: 2011-09-27 Impact factor: 6.860
Authors: Shakuntala Kondraganti; Christopher S Gondi; Meena Gujrati; Ian McCutcheon; Dzung H Dinh; Jasti S Rao; William C Olivero Journal: Int J Oncol Date: 2006-07 Impact factor: 5.650
Authors: Netanel A Horowitz; Elizabeth A Blevins; Whitney M Miller; Ashley R Perry; Kathryn E Talmage; Eric S Mullins; Matthew J Flick; Karla C S Queiroz; Kun Shi; C Arnold Spek; Edward M Conway; Brett P Monia; Hartmut Weiler; Jay L Degen; Joseph S Palumbo Journal: Blood Date: 2011-07-25 Impact factor: 22.113
Authors: Lois W Brüggemann; Henri H Versteeg; Tatjana M Niers; Pieter H Reitsma; C Arnold Spek Journal: J Cell Mol Med Date: 2008-03-20 Impact factor: 5.310
Authors: Adeel M Khan; Thita Chiasakul; Robert Redd; Rushad Patell; Ellen P McCarthy; Donna Neuberg; Jeffrey I Zwicker Journal: PLoS Med Date: 2022-05-25 Impact factor: 11.613